Trials / Completed
CompletedNCT03624127
Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 666 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986165 | Specified dose on specified days |
| OTHER | Placebo | Specified dose on specified days |
| DRUG | Apremilast | Specified dose on specified days |
Timeline
- Start date
- 2018-08-07
- Primary completion
- 2020-09-02
- Completion
- 2020-09-02
- First posted
- 2018-08-09
- Last updated
- 2023-01-30
- Results posted
- 2023-01-30
Locations
165 sites across 11 countries: United States, Canada, China, Germany, Japan, Poland, Russia, South Korea, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03624127. Inclusion in this directory is not an endorsement.